Abstract
Background: Previous studies have indicated the benefits of adding long acting ß2 agonists to inhaled corticosteroids in the maintenance treatment of moderate to severe asthma. The effects of adding eformoterol to corticosteroids on asthma control and exacerbations in patients with mild to moderate asthma were studied.
Methods: After a run in period of 7–14 days on existing medication, 663 symptomatic patients were randomised to receive budesonide Turbohaler 400 µg twice daily together with either eformoterol Turbohaler 9 µg (delivered dose) or placebo twice daily. After 4 weeks patients whose asthma was well controlled (n=505) were re-randomised to receive budesonide 400 µg daily and either eformoterol 9 µg or placebo twice daily for a further 6 months.
Results: Patients receiving eformoterol achieved asthma control 10 days sooner than those receiving budesonide alone, and improvements in lung function, symptoms, quality of life, and relief ß2 agonist use were significantly greater with eformoterol. During the 6 month follow up the frequency of mild exacerbations was significantly lower in the eformoterol group than in those receiving budesonide alone (7.2 versus 10.5 per patient, 95% confidence interval for ratio 0.49 to 0.96, p=0.03). The time to first day of poorly controlled asthma was 97 days in the eformoterol group compared with 42 days in the placebo group (p=0.003).
Conclusions: Adding eformoterol to a low or moderate dose of budesonide in mild asthma resulted in faster and more effective control than treatment with budesonide alone. Eformoterol allowed the corticosteroid dose to be reduced while also decreasing the rate of mild exacerbations compared with budesonide alone. These data suggest a therapeutic advantage of adding eformoterol to inhaled corticosteroids in patients with mild to moderate asthma.
Full Text
The Full Text of this article is available as a PDF (163.5 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Anderson G. P., Lindén A., Rabe K. F. Why are long-acting beta-adrenoceptor agonists long-acting? Eur Respir J. 1994 Mar;7(3):569–578. doi: 10.1183/09031936.94.07030569. [DOI] [PubMed] [Google Scholar]
- Guidelines on the management of asthma. Statement by the British Thoracic Society, the Brit. Paediatric Association, the Research Unit of the Royal College of Physicians of London, the King's Fund Centre, the National Asthma Campaign, the Royal College of General Practitioners, the General Practitioners in Asthma Group, the Brit. Assoc. of Accident and Emergency Medicine, and the Brit. Paediatric Respiratory Group. Thorax. 1993 Mar;48(2 Suppl):S1–24. doi: 10.1136/thx.48.2_suppl.s1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Juniper E. F., Guyatt G. H., Epstein R. S., Ferrie P. J., Jaeschke R., Hiller T. K. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax. 1992 Feb;47(2):76–83. doi: 10.1136/thx.47.2.76. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Juniper E. F., Guyatt G. H., Willan A., Griffith L. E. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol. 1994 Jan;47(1):81–87. doi: 10.1016/0895-4356(94)90036-1. [DOI] [PubMed] [Google Scholar]
- Maesen F. P., Smeets S. J., Costongs M. A., Zweers P. G., Pfeil J. P. Onset of action of eformoterol by dry powder inhaler: objective and subjective measures. Br J Clin Pract. 1995 Nov-Dec;49(6):294–296. [PubMed] [Google Scholar]
- Palmqvist M., Persson G., Lazer L., Rosenborg J., Larsson P., Lötvall J. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J. 1997 Nov;10(11):2484–2489. doi: 10.1183/09031936.97.10112489. [DOI] [PubMed] [Google Scholar]
- Pauwels R. A., Löfdahl C. G., Postma D. S., Tattersfield A. E., O'Byrne P., Barnes P. J., Ullman A. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med. 1997 Nov 13;337(20):1405–1411. doi: 10.1056/NEJM199711133372001. [DOI] [PubMed] [Google Scholar]
- Ringdal N., Derom E., Wåhlin-Boll E., Pauwels R. Onset and duration of action of single doses of formoterol inhaled via Turbuhaler. Respir Med. 1998 Aug;92(8):1017–1021. doi: 10.1016/s0954-6111(98)90348-1. [DOI] [PubMed] [Google Scholar]
- Seberová E., Andersson A. Oxis (formoterol given by Turbuhaler) showed as rapid an onset of action as salbutamol given by a pMDI. Respir Med. 2000 Jun;94(6):607–611. doi: 10.1053/rmed.2000.0788. [DOI] [PubMed] [Google Scholar]
- van Noord J. A., Smeets J. J., Raaijmakers J. A., Bommer A. M., Maesen F. P. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J. 1996 Aug;9(8):1684–1688. doi: 10.1183/09031936.96.09081684. [DOI] [PubMed] [Google Scholar]